特殊化疗策略或有助改善胶质瘤患者放疗后的疾病进展

  近日，来自梅奥诊所的研究人员开发了一种新型的化疗体系，该体系包括药物丙卡巴肼、洛莫司汀以及长春新碱，研究者表示，低级别胶质瘤的成年患者放疗后运用这种新型体系的化疗方法进行治疗可有效改善其无进展生存期及总体生存期，目前相关研究正在进行III期临床试验。
  Buckner博士表示，平均来讲，接受长春新碱治疗的病人可比仅进行放疗的患者多存活5.5年，在患者癌症诊断初期，放疗联合长春新碱进行治疗可以有效延长患者的无进展生存期但并不是总的生存期。
  文章中，研究者开展的名为RTOG9802的临床试验中招募了251名在1998年10月至2002年6月期间被诊断出的低级别胶质瘤患者，这些患者均在放疗后进行了相应的化学疗法；这些患者相比其它患者来讲患低级别胶质瘤的风险较高，因为其年龄都为40岁或40岁以上，而如果患者在40岁以下就可以利用外科手术完全移除肿瘤。
  研究者调查发现，相比星细胞瘤或寡星状细胞瘤患者而言，少突神经胶质瘤患者往往预后较高，RTOG9802临床研究体系包括了来自美国、加拿大等多个国家的研究人员，下一步研究人员计划对参与患者机体的肿瘤组织进行深入剖析研究来鉴别出新型的生物标志物，从而确定哪一类病人从特殊疗法中获益最多。
  据美国癌症学会数据显示，2014年在美国有将近2.3万人被诊断出原发性脑部肿瘤，其中10%至15%的患者为低级别胶质瘤，神经胶质瘤是一种起始于脑部或脊髓的肿瘤，也是原发性脑部肿瘤最为常见的形式。（转化医学网360zhyx.com）
  本文系转化医学网原创翻译整理，欢迎转载！转载请注明来源并附原文链接。谢谢！
转化医学网推荐的新闻阅读：

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the Society for Neuro-Oncology's 19th Annual Meeting in Miami by the study's primary author Jan Buckner, M.D., deputy director, practice, at Mayo Clinic Cancer Center.
"On average, patients who received PCV lived 5.5 years longer than those who received radiation alone," says Dr. Buckner. "These findings build on results published in the Journal of Clinical Oncology in 2012 and presented at the 2014 annual meeting of the American Society of Clinical Oncology, which showed that PCV given with radiation therapy at the time of initial diagnosis prolongs progression free-survival but not overall survival."
The trial, RTOG 9802, enrolled 251 patients with low-grade gliomas between October 1998 and June 2002 to address the role of chemotherapy following radiation treatment. Patients enrolled were at high risk compared to other low-grade glioma patients because they were 40 years of age or older or had a less than complete surgical removal of their tumor if they were under 40.....